Strategies used for MUC1 immunotherapy: preclinical studies
Strategies used for MUC1 immunotherapy: preclinical studies
复制标题
DOI：
10.1586/14760584.7.7.951
复制
发表时间：
2008-09
影响因子：
6.2
通讯作者：
C. Tang;V. Apostolopoulos
中科院分区：
文献类型：
--
作者：
C. Tang;V. Apostolopoulos
在过去的10-15年里，开发有效的抗癌免疫方法一直是研究的主要焦点。尽管在过去的10年中取得了令人印象深刻的进展，其中包括纯化的蛋白质，DNA和靶向树突状细胞和/或使用Toll样受体配体，但仍然有许多障碍需要克服，以引发可以完全根除癌细胞的有效免疫应答。MUC 1作为恶性肿瘤免疫治疗的靶标已经引起了人们的兴趣，所述恶性肿瘤包括实体癌，如乳腺癌、胰腺癌和卵巢癌，以及血癌，包括多发性骨髓瘤。许多方法已被证明在临床前环境中引起体液、细胞和肿瘤保护性应答。其中许多已进入人体临床试验，旨在评估MUC 1的免疫原性及其在许多恶性肿瘤免疫治疗/疫苗中的适用性。
The development of effective immunotherapeutic approaches against cancer has been a major focus of research in the last 10–15 years. Despite the impressive progress in the last 10 years, which has incorporated purified proteins, DNA and targeting to dendritic cells and/or the use of Toll-like receptor ligands, there are still many hurdles to overcome in order to elicit effective immune responses that could totally eradicate cancer cells. MUC1 has attracted interest as a target for immunotherapy of malignancies, including solid cancers, such as breast, pancreas and ovary, and blood cancers, including multiple myeloma. Numerous methods have been shown to elicit humoral, cellular and tumor protective responses in preclinical settings. Many of these have entered into human clinical trials, which aim to evaluate the immunogenicity of MUC1 and its suitability for use in immunotherapy/vaccine for many malignancies.